Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Областная клиническая психиатрическая больница №1, Тверь
Список исп. литературыСкрыть список 1. Кекелидзе З.И., Чехонин В.П. Критические состояния в психиатрии (клинические и иммуно-химические аспекты). М., 1997; с. 362. 2. Ромасенко В.А. Гипертоксическая шизофрения. М.,1967; с. 240. 3. Тиганов А.С. Фебрильная шизофрения. Клиника, патогенез, лечение. М., 1982; с. 128. 4. Addonizio G, Susman VL. ECT as treatment alternative for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychiatry 1987; 48: 102–5. 5. Addonizio G, Susman VL. Neuroleptic Malignant Syndrome: A Clinical Approach. St. Louis, MO: Mosby 1991. 6. Addonizio G, Susman VL, Roth SD. Neuroleptic Malignant Syndrome: Review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004–20. 7. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005; 28 (4): 197–204. 8. Adityanjee, Singh S, Singh G et al. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988; 153: 107–11. 9. Adnet PJ, Krivosic-Horber RM, Adamantidis MM et al. The association between the neuroleptic syndrome and malignant hyperthermia. Acta Anaesthesiol Scand 1989; 33: 676–80. 10. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85(1): 129–35. 11. Allen GC. Malignant hyperthermia: recognition and management of susceptible patients. Curr Opin Anaesthesiol 1996; 9: 271–5. 12. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test. The North American Malignant Hyperthermia Registry of MHAUS. Anaesthesiology 1998; 88: 579–88. 13. Allsop P, Jorfeldt L, Rutberg H, et al. Delayed recovery of muscle pH after short duration, high intensity exercise in malignant hyperthermia susceptible subjects. Br J Anaesth 1991; 66: 541–5. 14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Press 1994: 739–42. 15. Ames D, Wirshing WC. Ecstacy, the serotonin syndrome and neuroleptic malignant syndrome – a possible link? JAMA 1993; 269: 869–70. 16. Balzan MV. The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity. Postgrad Med 1998; 74: 72–6. 17.Benjelloun G, Jehel L, Abgrall G, et al. Acute catatonic syndrome after neuroleptic malignant syndrome. Encephale 2005; 31 (6 Pt 1): 705–9. 18. Benzer T. Neuroleptic Malignant Syndrome. eMedicine 2010. medscape.com/816018-overview 19. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004; 22 (2): 389–411. 20. Birmes P, Coppin D, Schitt L, et al. Serotonin syndrome: a brief review. CVAJ 2003; 168(11): 1439–42. 21. Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984; 3: 302–7. 22. Bottoni TN. Neuroleptic Malignant Syndrome: A Brief Review. Hospital Physician March 2002: 58–63. www.turner-white.com 23. Bourdon L, Canini F. On the nature of the link between malignant hyperthermia and exertional heat stroke. Med Hypotheses 1995; 45: 268–70. 24. Boyer EW, Shannon M. Current Concepts: The Serotonin Syndrome. New Engl J Med 2005; 352 (11): 1112–20. 25. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996; 30: 527–33. 26. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18 (2): 317–25. 27. Caroff SN. Neuroleptic malignant syndrome. In: Mann SC, Caroff SN, Lazarus A, editors. Neuroleptic Malignant Syndrome and Related Conditions, 2nd ed. Washington DC: American Psychiatric Publishing 2003: 1–44. 28. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77 (1): 185–202. 29.Caroff SN, Mann SC, Campbell EC. Neuroleptic malignant syndrome: copyright 2001 Lippincott Williams and Wilkins. In Adverse Drug Reaction Bulletin 2001; 209: 799–802. 30. Caroff SN, Rosenberg H, Mann SC. Neuroleptic malignant syndrome in the critical care unit. Crit Care Med 2002; 30 (11): 2609, author reply 2609–10. 31. Caroff SN, Rosenberg H, Mann SC, et al. Neuroleptic malignant syndrome in the perioperative setting. Am J Anesthesiol 2001; 28:387–93. 32. Carroll BT, Lee JW, Graham KT, et al. Diagnosing subtypes of neuroleptic malignant syndrome: an introduction to the Lee-Carroll Scale. Ann Clin Psychiatry 2008; 20 (1): 47–8. 33. Casamassima F, Lattanzi L, Perlis RH et al. Neuroleptic malignant syndrome: further lessons from a case report. Psychosomatics 2010; 51 (4): 349–54. 34. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am. J. Psychiatry 1989; 146: 324–8. 35. Chakrabarti S, Sharma D, Singh G. Neurological Sequelae of Neuroleptic Malignant Syndrome. Hong Kong J Psychiatry 2001; 11 (3): 18–20. 36.Chan BS, Graudins A, Whyte IM et al. Serotonin syndrome resulting from drug interactions. Med J Aust 1998; 169: 523–5. 37. Chan TC, Evans SD, Clark RF. Drug-induced hyperthermia. Crit Care Clin 1997; 13: 785–808. 38. Chandran M, El-Shazly M. Catatonia, neuroleptics and brain damage – a case report. J Psychopharmacol 2009; 23 (2): 223–6. 39. Chandran GJ, Mikler JR, Keegan Dl. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003; 169 (5): 439–42. 40. Dave M. Two cases of risperidone-induced neuroleptic malignant syndrome (ltr). Am J Psychiatry 1995; 152: 1233–4. 41. Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr Ann 2000: 30: 325–31. 42. Davis JM, Janicak PG, Sakkas H et al. Electroconvulsive Therapy in the Treatment of Neuroleptic Malignant Syndrome. Convuls Ther 1991; 7 (2): 111–20. 43. Demirkiran M, Jankovic J, Dean JM. Ecstacy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 1996; 19: 157–64. 44. Denborough M. Malignant hyperthermia. Lancet 1998; 352: 1131–6. 45. Denborough MA, Collins SP, Hopkinson KC. Rhabdomyolysis and malignant hyperpyrexia. Br Med J Clin Res Ed 1984; 288: 1878. 46. Denborough MA, Hopkinson KC, Banney DG. Firefighting and malignant hyperthermia. Br Med J Clin Res Ed 1988; 296: 1242–3. 47.Dent J. Catatonic syndrome following recovery from neuroleptic malignant syndrome. J Intellect Disabil Res 1995; 39 (Pt 5): 457–9. 48. Draper R. Neuroleptic malignant syndrome. 2009. www.patient.co.uk/showdoc 49. Ellis FR, Campbell IT. Fatal heat stroke in a long distance runner (letter). Br Med J 1983; 287: 1548–9. 50. Ener RA, Meglathery SB, Van Decker, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med 2003; 4 (1): 63–74. 51. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperthermia susceptibility. Br J Anaesth 1984; 56: 1267–9. 52. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry 1996; 39: 1–4. 53. Fleischhacker WW, Unterweger B, Kane JM et al. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990; 81(1): 3–5. 54. Francis A, Koch M, Chandragiri S et al. Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr 2000; 5: 54–7. 55. Fuller MA, Sajatovic M. Drug Information for Mental Health. Cleveland 2001. 56. Geiduschek J, Cohen SA, Khan A, Cullen BF. Repeated anesthesia for a patient with neuroleptic malignant syndrome. Anesthesiology 1988; 68: 134–7. 57. Gelenberg AJ, Bellinghausen B, Wojcik JD et al. Patients with neuroleptic malignant syndrome histories: what happens when they are rehospitalized? J Clin Psychiatry 1989; 50: 178–80. 58. George L, Wood CA. Succinylcholine induced hyperkalemia complicating the neuroleptic malignant syndrome. Ann Intern Med 1987; 106: 172–6. 59. Ghaziuddin N, Alkhouri I, Champine D et al. ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment. J ECT 2002; 18 (2): 95–8. 60. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998; 12 (5): 482–91. 61.Giménez AL, Gates RJ, Diaz JF et al. Lethal catatonia and its differential diagnosis with the neuroleptic malignant syndrome. Rev Neurol 2002; 34 (4): 399–400. 62. Gold R, Lenox RH. Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. J Clin Psychiatry 1995; 56: 476–83. 63. Granner MA, Wooten GF. Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Semin Neurol 1991; 11 (3): 228–35. 64. Gronert GA, Antognini JF, Pessah IN. Malignant hyperthermia. In: Miller RD, editer. Anesthesia. 5th Edition. New York. Churchill Livingston 2000: 1033–52. 65. Gronert GA, Thompson RL, Onofrio BM. Human malignant hyperthermia: Awake episodes and correction by dantrolene. Anesth Analg 1980; 59: 377–8. 66. Gupta S, Nihalani ND. Neuroleptic Malignant Syndrome: A Primary Care Perspective. J Clin Psychiatry 2004; 6 (5): 191–4. 67. Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002; 25 (4): 183–93. 68. Hackl W, Winkler M, Mauritz W et al. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Br J Anaesth 1991; 66: 138–40. 69. Hall RC, Appledy B, Hall RC. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005; 98 (1): 114–7. 70. Hall RCW, Chapman M. Neuroleptic Malignant Syndrome in the Elderly. Diagnostic Criteria, Incidence, Risk Factors, Pathophysiology, and Treatment. Clin Geriatrics 2006; 14 (5): 39–46. 71. Hammergren DJ. Neuroleptic malignant syndrome: an online resource for healthcare providers. The university of Arizona 2006: 61. 72. Harada T, Mitsuoka K, Kumagai R, et al. Clinical fealures of malignant syndrome in Parkinson’s disease and related neurological disorders. Parkinsonism Relat Disord 2003; 9 (suppl 1): S15–23. 73. Hasan S, Buckley P. Novel Antipsychotics and the Neuroleptic Malignant Syndrome: A Review and Critique. Am J Psychiatry 1998; 155: 1113–9. 74.Haverkort-Poels PJ, Joosten EM, Ruitenbeek W. Prevention of recurrent exertional rhabdomyolysis by dantrolene sodium. Muscle Nerve 1987; 10: 45–6. 75. Heils A, Lesch KP. Neuroleptic malignant syndrome and acute life-threatening catatonia – two contrasting disease entities? Fortschr Neurol Psychiatr 1997; 65 (1): 8–15. 76. Heiman-Patterson TD. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am 1993; 77: 477–89. 77. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathophysiologic role for the dopamine receptor blockade? Neurology 1981; 1331: 132–7. 78. Hermesh H, Aizenberg D, Wiezman A. A successful electroconvulsive treatment of neuroleptic malignant syndrome. Acta Psychiatr Scand 1987; 75: 237–9. 79. Hermle L, Oepen G. Differential diagnosis of acute life threatening catatonia and malignant neuroleptic syndrome – a case report. Fortschr Neurol Psychiatr 1986; 54 (6): 189–95. 80. Heyland D, Sauve M. Neuroleptic malignant syndrome without the use of neuroleptics. CVAJ 1991; 145: 817–9. 81.Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 1991; 338: 1491–2. 82. Huang TL, Ree SC, Huang YC et al. Catatonic features: Differential diagnosis and treatments at an emergency unit. Psychiatry Clin Neurosci 1999; 53 (1): 63–6. 83. Hughes JR. ECT during and after the neuroleptic malignant syndrome: Case report. J Clin Psychiatry 1986; 47: 42–3. 84. Hüttemann K, Nowe T, Köhrmann M et al. Maligne Hyperthermie und deren Differenzialdiagnosen. Fortschr Neurol Psychiatr 2009; 77 (4): 203–11. 85. Ihara V, Kohara N, Urano F et al. Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient. Neurology 2002; 59 (7): 1102–4. 86. Iwuagwu C, Riley D, Bonoma R. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a catechol-o-methyl transferase inhibitor. Am J Med 2000; 108 (6): 517–8. 87. Jardon OM. Physiologic stress, heat stroke, malignant hyperthermia: A perspective. Military Med 1982; 147: 8–14. 88. Johnson DH, Cunha BA. Drug fever. Infect Dis Clin North Am 1996; 10: 85–91. 89. Kasantikul D, Kanchanatawan D. Neuroleptic malignant syndrome: a review and report of six cases. J Med Ass Thailand 2006; 89 (12): 2155–60. 90. Kaufman Kr, Levitt MJ, Schiltz JF, Sunderram J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann Clin Psychiatry 2006; 18 (3): 201–4. 91.Keck PE Jr, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia: End of a controversy? J Neuropsychiatry Clin Neurosci 1995; 7 (2): 135–44. 92. Khaidi S, Kornreich C, Choubani Z et al. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale 2008; 34 (6): 618–24. 93. Khan HM, Syed NA, Sheerani M, et al. Neuroleptic malignant syndrome: need for early diagnosis and therapy. J Ayub Med Coll Abbottabad 2006; 18(1): 17–21. 94. Kliesser E et al. 1992 – Цит. по З.И. Кекелидзе, В.П. Чехонину, 1997. 95. Köchling A, Wappler F, Winkler G et al. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care 1998; 26: 315–8. 96. Kojima Y, Oku S, Takahashi K et al. Susceptibility to malignant hyperthermia manifested as delayed return to increased creatine kinase activity and episode rhabdomyolysis after exercise. Anesthesiology 1997; 87: 1565–7. 97. Konikoff F, Kuritzky A, Jerushalmi Y et al. Neuroleptic malignant syndrome induced by single injection of haloperidol (ltr). Brit Med J 1984; 289: 1228–9. 98. Kozack JK, Macintyre DL. Malignant hyperthermia. Phys Ther 2001; 81: 945–51. 99. Lazarus A, Mann SC, Caroff SN. The Neuroleptic Malignant Syndrome and Related Conditions. Washington, DC: American Psychiatric Press 1989. 100.Lee J. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44 (6): 499–507. 101. Lee JW. Catatonic variants hyperthermic extrapyramidal reactions and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry 2007; 19 (1): 9–16. 102. Lee JW. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol 2010; 30 (1): 3–10. 103. Legras A, Hurel D, Dabrowski G et al. Protracted neuroleptic malignant syndrome complicating long-acting neuroleptic administration. Am J Med 1988; 85: 875–8. 104.Leong P, MacLennan DH. The cytoplasmic loops between domains II and III and domains III and IV in the skeletal muscle dihydropyridine receptor bind to a contiquous site in the skeletal muscle ryanodine receptor. J Biol Chem 1998; 273: 29958–64. 105.Lev R, Clark RF. Neuroleptic malignant syndrome presenting without fever: case report and review of the literature. J Emerg Med 1994; 12: 49–55. 106. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137–45. 107. Levenson JL. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome (ltr). Am J Psychiatry 1989; 146: 1241. 108. Levenson JL, Fisher JG. Long-term outcome after neuroleptic malignant syndrome. J Clin Psychiatry 1988; 49: 154–6. 109.Lheureux P, Penaloza A, De Cottenier V et al. Serotonin syndrome. Rev Med Brux 2002; 23 (5): 422–8. 110. LoCurto MJ. The serotonin syndrome. Emerg Med Clin North Am 1997; 15: 665–74. 111. Loke JCP, MacLennan DH. Bayesian modeling of muscle biopsy contracture testing for malignant hyperthermia susceptibility. Anesthesiology 1998; 88: 589–600. 112. Mann SC, Auriacombe M, Macfadden W, et al. Lethal catatonia: clinical aspects and therapeutic intervention. A review of the literature. Encephale 2001; 27 (3): 213–6. 113. Mann SC, Caroff SN, Bleier HR et al. Lethal catatonia. Am J Psychiatry 1986; 143: 1374–81. 114. Mann SC, Caroff SN, Keck PE et al. Neuroleptic Malignant Syndrome and Related Conditions. 2th ed. Washington, DC: American Psychiatric Publishing 2003. 115. Margetić B, Aukst- Margetić B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010; 19 (5): 429–35. 116. Martin TG. Serotonin syndrome. Ann Emerg Med 1996; 28 (5): 520–6. 117. McHung TP. Neuroleptic malignant syndrome. J S C Med Assoc 1992; 88 (6): 303–6. 118. Medication-induced movement disorders: Neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association 2000: 795–8. 119. Mills K. C. Serotonin syndrome: a clinical update. Crit Care Clin 1997; 13: 763–83. 120. Miyatake R, Iwahashi K, Matsushita M et al. No association between the neuroleptic malignant syndrome and mutations in the RYR I gene associated malignant hyperthermia. J Neurol Sci 1996; 143: 161–5. 121. Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome: successful treatment with bromocriptine. J Am Med Assoc 1983; 249: 386–8. 122. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine (letter). Lancet 1988; 2: 1500. 123. Murak E. Neuroleptic malignant syndrome. Psychiatr Pol 1995; 29 (3): 349–58. 124. Neuroleptic Malignant Syndrome (NMS). psyweb.com/glossary/nms.jsp 125. Neuroleptic malignant syndrome. Wikipedia 2010. http://www.answers.com/library/Wikipedia-cid-2885799 126. Nicholson D, Chiu W. Neuroleptic malignant syndrome. Geriatrics 2004; 59 (8): 36, 38–40. 127. Nielsen C, Mazzone P. Muscle pain after exercise. Lancet 1999; 353: 1062. 128. Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 2002; 109 (12): 1453–67. 129. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf 2009; 4 (1): 84–93. 130. Ogletree JW, Antognini JF, Gronert GA. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am J Sports Med 1996; 24: 49–51. 131. Osman AA, Khurasani MH. Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis. Br J Psychiatry 1994; 165 (4): 548–50. 132. Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991; 158: 850–3. 133. Ozer F, Meral H, Aydin B et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005; 21 (2): 125–7. 134. Paparrigopoulos T, Tzavellas E, Ferentinos P et al. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009; 10 (1): 70–3. 135. Patel AL, Shaikh WA, Khobragade AK et al. Electroconvulsive Therapy in Drug Resistant Neuroleptic Malignant Syndrome. JAPI 2008; 56: 49–50. 136. Patel U, Agrawal M, Krishnan P et al. Niranjan S. Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrhea. J Nat Med Assoc 2002; 94 (4): 279–82. 137. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic Malignant Syndrome: A Review. Psychiatr Serv 1998; 49 (9): 1163–72. 138. Pelonero AL, Levenson JL, Silverman JJ. Neuroleptic therapy following neuroleptic malignant syndrome. Psychosomatics 1985; 26: 946–8. 139. Persing JS. Neuroleptic malignant syndrome: an overview. S D J Med 1994; 47: 51–5. 140. Pope HG, Aizley HG, Keck PE, McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry 1991; 52: 208–12. 141. Pope HG, Cole JO, Choras PT et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493–5. 142. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143: 1227–33. 143. Reulbach U, Dutsch C, Biermann T et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007; 11: R4 (e-pub Jan 12, 2007). 144. Richard IH. Acute, drug-induced, life-threatening neurological syndromes. The Neurologist 1998; 4: 196–210. 145. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991; 338 (8760): 149–151. 146. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic recallendges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989; 50: 295–8. 147. Rosenberg VR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989; 149: 1927–31. 148. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res 2005; 135 (3): 249–56. 149. Sachdev P, Kruk J, Kneebone M et al. Clozapine-induced neuroleptic malignant syndrome; review and report of new cases. J Clin Psychopharmacol 1995; 15: 365–71. 150. Sakamoto A, Hoshino T, Suzuki H et al. Repeated propofol anesthesia for a patient with a history of neuroleptic malignant syndrome. J Nippon Med Sch 1999; 66 (4): (262–5) 44–7. 151. Sakkas P, Davis JM, Hua J et al. Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr Ann 1991; 21: 157–64. 152. Sakkas P, Davis JM, Janicak PG et al. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27: 381–4. 153. Sanmaneechai O, Likasitwattanakul S. Neuroleptic malignant syndrome: a report of 2 cases. Chiang Mai Med Bull 2005; 44 (2): 73–8. 154. Sato Y, Asoh N, Metoki N et al. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003; 74 (5): 574–6. 155. Saunders BP, Trewby PN. The neuroleptic malignant syndrome: a missed diagnosis? Br J Clin Pract 1993; 47: 170–1. 156. Scarlett JD, Zimmerman R, Berkovic SF. Neuroleptic malignant syndrome. Aust N Z J MED 1983; 13: 70–3. 157. Scheftner WA, Shulman RB. Treatment Choice in Neuroleptic Malignant Syndrome. Convuls Ther 1992; 8 (4): 267–79. 158. Schröder J, Schröder J, Linge C et al. Differential diagnosis of malignant hyperthermia, febrile catatonia and neuroleptic malignant syndrome. A case comparison. Fortsch Neurol Psychiatr 1988; 56 (3): 97–101. 159. Sessler DI. Malignant hyperthermia. Acta Anaesthesiol Scand Suppl 1996; 109: 25–30. 160. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50: 18–25. 161. Singer S, Richards C, Boland RJ. Two cases of risperidone-induced neuroleptic malignant syndrome (ltr). Am J Psychiatry 1995; 152: 1234. 162. Stauder KH. Die tödliche Katatonie. Arch Psychiat Nervenkr 1934; 102: 614–34. 163. Sternbach H. Serotonin Syndrome: How to avoid, identify and treat dangerous drug interactions. Evidence Based Reviews 2033; 2(5). – Цит. по D. J. Hammergren, 2006. 164. Strawn JR. Aripiprazole and the neuroleptic malignant syndrome. Schizophr Res 2006; 85: 298–9. 165. Strawn JR, Keck PE. Early bicarbonate loading and dantrolene for ziprasidone/haloperidol-induced neuroleptic malignant syndrome (letter). J Clin Psychiatry 2006; 67:677. 166. Strawn JR, Keck PEº Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164 (6): 870–6. 167. Stubner S, Rustenbeck E, Grohmann R et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004; 37 (suppl 1): 54–64. 168. Susman VL. Clinical Management of Neuroleptic Malignant Syndrome. Psychiatric Quarterly 2001; 72: 325–36. 169. Susman VL, Addonizio G. Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis 1988; 176: 234–41. 170. Takubo H, Harada T, Hashimoto T et al. A collaborative study on the malignant syndrome in Parkinson’s disease and related disorders. Parkinsonism Relat Disord 2003; 9 (suppl 1): 31–41. 171. Taylor NE, Schwartz HI. Neuroleptic malignant syndrome following amoxapine overdose. J Nerv Ment Dis 1988; 176: 249–51. 172. Terlikowska M, Marzański M. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome: a case report. Psychiatr Pol 1995; 29 (3): 343–8. 173. Tollefson G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol 1982; 2: 266–70. 174. Tonkonogy J., Sholevar DP. Neuroleptic Malignant Syndrome. eMedicine 2010. medscape.com/article/288482-overview 175. Topka H, Buchkremer G. Catatonia, malignant neuroleptic syndrome and myositis ossificans. Nervenarzt 1996; 67 (5): 413–7. 176. Totten VY, Hirschenstein E, Hew P. Neuroleptic malignant syndrome presenting without initial fever: a case report. J Emerg Med 1994; 12: 43–7. 177. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23 (6): 477–92. 178. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33: 650–9. 179. Tsai HC, Kuo PH, Yang PC. Fever, consciousness disturbance, and muscle rigidity in a 68-year-old man with depressive disorder. Chest 2003; 124 (4): 1598–601. 180. Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci 2010; 64 (1): 79–87. 181. Vancaester E, Santens P. Catatonia and neuroleptic malignant syndrome: two sides of a coine? Acta Neurological Belgica 2007; 107 (2): 47–50. 182. Velamoor VR. Neuroleptic malignant syndrome. Drug Saf 1998; 19: 73–82. 183. Velamoor VR, Norman RM, Caroff SN et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994; 182: 168–73. 184. Vesperini S, Papetti F, Pringuey D. Are catatonia and neuroleptic malignant syndrome related conditions?. Encephale 2010; 36 (2): 105–10. 185. Waldorf S. Update for nurse anesthetists, Neuroleptic Malignant Syndrome. AANA J 2003; 71: 389–94. 186. Wappler F, Fiege M, Steinfath M et al. Evidence for Susceptibility to Malignant Hyperthermia in Patients with Exercise-induced Rhabdomyolysis. Anesthesiology 2001; 94 (1): 95–100. 187. Westphal RJ. Serotonin Syndrome. J Am Psychiatr Nurs Assoc 1999; 5: 97–102. 188. White DA. Catatonia and neuroleptic malignant syndrome – a single entity? Br J Psychiatry 1992; 161: 558–60. 189. White DAC, Robins AH. Catatonia: harbinger of neuroleptic malignant syndrome. Br J Psychiatry 1991. www.fags.org 190. Wingard DW. Malignant hyperthermia: A human stress syndrome? Lancet 1974; 2: 1450–1. 191. Woodbury MM, Woodbury MA: Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31:1161–4. 192. Wren P, Frizzell LA, Keltner NL et al. Three Potentially Fatal Adverse Effects of Psychotropic Medications. Persp Psychiatr Care 2003; 36. – Цит. по D.J. Hammergren, 2006. 193. Yacoub A, Kohen I, Caraballo A et al. Rating Scale Neuroleptic Malignant Syndrome. Biol Psychiatry 2004; 55: 89. 194. Yanagawa Y, Miyazaki M. Case with difficulty in differentiation between transient neuroleptic malignant syndrome and catatonia after neuroleptic analgesia. Masui 2010; 59 (2): 235–7.